We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Athira Pharma Inc
16 own
10 watching
Current Price
$3.8
$-0.42
(-9.95%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
143.71M
52-Week High
14.22
52-Week Low
2.53
Average Volume
0.69M
Dividend Yield
--
P/E Ratio
--
Market Capitalization143.71M52-Week High14.2252-Week Low2.53Average Volume0.69MDividend Yield--P/E Ratio--What does the Athira Pharma Inc do?
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company s lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Read More
How much money does Athira Pharma Inc make?
News & Events about Athira Pharma Inc.
Globe Newswire
29days ago
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimers disease is progressing with targeted enrollment ...
Globe Newswire
1month ago
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal modelsBOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused ...
Ticker Report
1month ago
Shares of Athira Pharma, Inc. (NASDAQ:ATHA Get Rating) have been given a consensus recommendation of Moderate Buy by the six analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned...
Globe Newswire
1month ago
PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (Athira or the Company) (NASDAQ: ATHA) on behalf of the Companys long-term investors. The investigation seeks to determine whether the members of Athiras board of directors violated...
Globe Newswire
2 months ago
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST, a composite score of cognition (ADAS-Cog11) and function (ADCS-ADL23) Data demonstrate fosgonimeton ...
Frequently Asked Questions
Frequently Asked Questions
What is Athira Pharma Inc share price today?
Can Indians buy Athira Pharma Inc shares?
How can I buy Athira Pharma Inc shares from India?
Can Fractional shares of Athira Pharma Inc be purchased?
What are the documents required to start investing in Athira Pharma Inc stocks?
What is today’s traded volume of Athira Pharma Inc?
What is today’s market capitalisation of Athira Pharma Inc?
What is the 52-Week High and Low Range of Athira Pharma Inc?
What percentage is Athira Pharma Inc down from its 52-Week High?
What percentage is Athira Pharma Inc up from its 52-Week Low?
Current Price
$3.8
$-0.42
(-9.95%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.